Figure 6.

Pairing a membrane-proximal epitope of MSLN to a CD47-blocking arm results in an efficient disruption of the CD47/SIRPα axis and enhances the phagocytosis potential of a MSLNxCD47 bsAb. ADCP dose-–response curve mediated by the CD47xMSLN bsAb#1 (a) or bsAb#2 (b) compared to their respective monovalent variants containing only the CD47 arm or anti-MSLN arm. A representative experiment (among four independent donors used as a source of effector cells) is depicted in the figure. In specific experiments, target cells were incubated in the presence of the indicated full length or F(ab’)2 fragments (tested at 10 μg/mL) (c). The anti-MSLN mAb 7D9 is tested at suboptimal concentration (3 ng/mL) either alone or combined to B6H12, CD47xMSLN bsAb#1 or bsAb#2 F(ab’)2 fragments (tested at 10 μg/ml each). Graph depicts a summary of four independent experiments (C). Statistical analysis was performed using the unpaired T test: *p < .05, **p < .01, ns = not significant.